AbFero Pharmaceuticals is a privately-held clinical stage pharmaceutical company dedicated to treating diseases of iron overload. Our therapeutic platform addresses transfusion-related iron overload (TIO) and iron accumulation associated with diseases of aging, such as age-related macular degeneration (AMD), and Parkinson’s disease. AbFero has completed three clinical trials with the company’s lead iron chelator, SP-420. AbFero Pharmaceuticals, Inc., is based in Boston, Massachusetts, and our subsidiary, AbFero, Ltd., is located in Harwell, UK.
Company Details
- Employees
- 2
- Address
- Boston, Us
- Industry
- Biotechnology
- Website
- abfero.com
- Keywords
- Harwell Campus.
- HQ
- Boston
Abfero Pharmaceuticals, Inc. Questions
Abfero Pharmaceuticals, Inc.'s website is abfero.com
Abfero Pharmaceuticals, Inc.'s LinkedIn profile is https://www.linkedin.com/company/abfero-pharmaceuticals
Abfero Pharmaceuticals, Inc. has
2 employees.
View email and phone details for 2
employees at Abfero Pharmaceuticals, Inc..
Abfero Pharmaceuticals, Inc.'s industry is
Biotechnology
Abfero Pharmaceuticals, Inc.'s top competitors are
Ridgeway Kite,
Waferpath, Inc.,
Scitech Precision Limited,
Sachsen-Kälte Gmbh,
Aquobex Ltd,
Chc Pharmaceuticals,
Aoi Electronics Co., Ltd.,
Mariposa Therapeutics,
Ams Micromedical,
Eosphere Limited.
Abfero Pharmaceuticals, Inc.'s categories are Biotechnology
